WHO Sounds Alert Over Critical Lack of Obesity Jabs
Fewer than a tenth of patients that would benefit from weight-loss injections such as Wegovy are able to get them, states the global health agency as it publishes its first recommendations on the medications.
Considering in excess of 1,000,000,000 people worldwide now living with obesity, it is advocating for increased and just availability to GLP-1 medication.
Per projections, more than two billion will be living with obesity by 2030 without intervention.
"Our new guidelines acknowledges that obesity is a chronic disease that can be addressed with holistic and continuous care," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are key barriers to broad access to the injections that can help people shift significant body mass, says the agency.
GLP-1 Therapy Scarcity
Despite the current most favorable outlook, the production of such drugs might only reach about 100 million people – under 10% of eligible patients, according to the WHO.
The guideline calls on nations and manufacturers to expand availability, through approaches such as patent sharing.
Exclusive production rights on a key compound – the primary ingredient of Novo Nordisk's Wegovy – is due to expire in several nations in 2026.
How Weight-Loss Jabs Operate
GLP-1 drugs replicate a body's own hormone to reduce digestion speed, reduce hunger and boost feelings of fullness so individuals consume fewer calories.
Individuals typically begin shedding pounds in the initial weeks of starting on the weekly injections.
Studies indicates users may regain a significant portion after a year of discontinuing the treatment, because their usual appetite come back.
To be overweight or obese elevates your likelihood for developing health problems, including type 2 diabetes, cardiovascular issues, stroke, and specific cancers.
Excess weight impacts individuals in all nations and was associated with over three and a half million deaths worldwide in 2024, per the health agency.